Novel Extended-spectrum β-Lactamase in Shigella sonnei by Lefort, Agnes et al.
LETTERS
Acknowledgments
We dedicate this work to the late
Andrew Spielman, our coauthor and
beloved mentor. We thank J. Rivero, I.
Pérez, M. Méndez, I. Matheus, M. Aguiar
de Bracho, I. Carreño, J.M. Hernández, A.
Nagy, A. Suarez, N. Moncada, M.
Kilpatrick, E. Rodriguez, E. Marquez, E.
Marian, B. Hernández; C. Rivero-Blanco,
M. Azar, J. Rodriguez, H. Montañez, F.
Alfonzo, and G. Rangel for their contribu-
tions to this study; and the Centro de
Investigaciones Biomédicas, Universidad
de Carabobo and the Cell Culture Core of
Wadsworth Center, New York State
Health Department, for their support. We
also thank ProFauna and the National
Institute of Parks in Venezuela for permis-
sion to obtain mosquito and bird samples.
This study was supported by grant
AI45440 from the National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, and an International
Collaborations in Infectious Disease
Research opportunity pool grant.
Irene Bosch,* Flor Herrera,† 
Juan-Carlos Navarro,‡ 
Miguel Lentino,§ Alan Dupuis,¶#
Joseph Maffei,¶# Matthew Jones,¶# 
Ernesto Fernández,** 
Nelson Pérez,†† Jorge Pérez-Emán,‡
Anthony Érico Guimarães,‡‡
Roberto Barrera,§§ 
Nereida Valero,¶¶ Johanny Ruiz,†
Glenda Velásquez,## Juán Martinez,‡ 
Guillermo Comach,† 
Nicholas Komar,*** 
Andrew Spielman,†††1
and Laura Kramer¶#
*University of Massachusetts Medical
School, Worcester, Massachusetts, USA;
†Universidad de Carabobo Biomed,
Maracay, Venezuela; ‡Universidad Central
de Venezuela, Caracas, Venezuela;
§Coleccion Ornitologica Phelps, Caracas,
Venezuela; ¶New York State Department of
Health, Albany, New York, USA; #State
University of New York at Albany, Albany,
New York, USA; **Universidad Central de
Venezuela, Maracay, Venezuela;
††Instituto Nacional de Investigaciones
Agrícolas, Maracay, Venezuela; ‡‡Instituto
Oswaldo Cruz, Rio de Janeiro, Brazil;
§§Centers for Disease Control and
Prevention, San Juan, Puerto Rico, USA;
¶¶Universidad del Zulia, Maracaibo,
Venezuela; ##Ministerio de Salud Insalud,
Carabobo, Venezuela; ***Centers for
Disease Control and Prevention, Fort
Collins, Colorado, USA; and ††† Harvard
School of Public Health, Boston,
Massachusetts, USA
References
1.  Hayes EB, Komar N, Nasci RS,
Montgomery SP, O’Leary DR. Campbell
GLEpidemiology and transmission dynam-
ics of West Nile virus disease. Emerg Infect
Dis. 2005;11:1167–73.
2. Komar N, Clark GG. West Nile virus activ-
ity in Latin America and the Caribbean.
Rev Panam Salud Publica. 2006;19:112–7.
3. Morales-Betoulle ME, Morales H, Blitvich
BJ, Powers AM, Davis EA, Klein R, et al.
West Nile virus in horses, Guatemala.
Emerg Infect Dis. 2006;12:1038–9.
4. Mattar S, Edwards E, Laguado J, Gonzalez
M. Alvarez J, Komar N. West Nile virus
antibodies in Colombian horses. Emerg
Infect Dis. 2005;11:1497–8.
5. Morales MA, Barrandeguy M, Fabbri C,
Garcia GB, Vissani A, Trono K, et al. West
Nile virus isolation from equines in
Argentina, 2006. Emerg Infect Dis.
2006;12:1559–61.
6. Ebel GD, Dupuis AP II, Nicholas D, Young
D. Maffei J, Kramer LD. Detection by
enzyme-linked immunosorbent assay of
antibodies to West Nile virus in birds.
Emerg Infect Dis. 2002;8:979–82.
7.  Dupuis AP II, Marra PP, Kramer LD.
Serologic evidence of West Nile virus
transmission, Jamaica, West Indies. Emerg
Infect Dis. 2003;9:860–3.
8. Figueiredo LT. The Brazilian flaviviruses.
Microbes Infect. 2000;2:1643–9.
9.  Kuno G, Chang GJ, Tsuchiya KR,
Karabatsos N, Cropp CB. Phylogeny of the
genus Flavivirus. J Virol. 1998;72:73–83.
10. Calisher CH, Monath TP. Karabatsos N,
Trent DW. Arbovirus subtyping: applica-
tions to epidemiologic studies, availability
of reagents, and testing services. Am J
Epidemiol. 1981;114:619–31.
Address for correspondence: Irene Bosch,
Center for Infectious Disease and Vaccine
Research, University of Massachusetts
Medical School, 55 Lake Ave North,
Worcester, MA 01655, USA: email: Irene.
bosch@umassmed.edu
Novel Extended-
spectrum 
β β-Lactamase in
Shigella sonnei
To the Editor: A 38-year-old
French man with a history of chronic
juvenile arthritis was referred to the
Necker-Enfants Malades University
hospital (Paris, France) with a dysen-
teric syndrome. The patient had
returned the day before from a 1-
month stay in Port-au-Prince, Haiti,
where he spent most of his time in
close contact with young children
from an orphanage, most of whom
had diarrhea. Clinical examination at
admission showed fever (39°C),
chills, diffuse abdominal pain, bloody
diarrhea, and vomiting. The patient
received ceftriaxone, which was
stopped on day 4 because initial blood
and stool cultures were negative for
pathogens and clinical signs had com-
pletely resolved. 
Ten days later, he reported the
recurrence of diarrhea without fever.
A novel stool culture grew Shigella
sonnei. An extended-spectrum β-lac-
tamase (ESBL) was detected by dou-
ble-disk synergy test; the isolate was
also resistant to aminoglycosides
(except amikacin), tetracycline, and
cotrimoxazole. The strain was suscep-
tible to fluoroquinolones and fos-
fomycin. It also appeared susceptible
to azithromycin (MIC 4 µg/mL),
although azithromycin MIC for
Shigella spp. should be interpreted
with caution (1). The patient was suc-
cessfully treated with azithromycin at
a dose of 500 mg/day for 5 days.
Azithromycin was preferred to fluoro-
quinolones to avoid the risk for
tendinopathy because of the patient’s
history of chronic juvenile arthritis
and because this antimicrobial agent
was shown to be effective in the treat-
ment of shigellosis caused by mul-
tidrug-resistant strains (2). 
To identify the molecular basis of
this ESBL, a series of PCR primers
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were used for detection of TEM-,
SHV-, or CTX-M–type ESBL (3).
Only the TEM PCR showed positive
results. Sequencing of 2 independent
PCR products showed a new allele
(www.lahey.org/studies/temtable.asp).
Analysis of the deduced amino acid
sequence allowed characterization of
TEM-137, derived from TEM-1 with
2 substitutions, Arg-16→Ser and Glu-
240→Arg. This ESBL (and resistance
to aminoglycosides and tetracyclines)
was easily transferred to Escherichia
coli J53-2 by conjugation.
MICs of β-lactams alone or in
association with clavulanic acid, were
determined by E-test, according to
manufacturer’s instructions (AB
Biodisk, Solna, Sweden). High-level
resistance to ceftazidime (MIC 32
µg/mL) and intermediate resistance to
cefotaxime (MIC 8 µg/mL) were
observed; the strain remained suscep-
tible to cefepime and imipenem (MIC
0.5 and 0.25 µg/mL, respectively).
Clavulanic acid did not restore sus-
ceptibility to ceftazidime (MIC 4
µg/mL) but did restore susceptibility
to cefotaxime (MIC 0.5 µg/mL). With
clavulanic acid, the MIC of cefepime
was 0.06 µg/mL.
ESBL in S. sonnei is rare world-
wide. In Argentina, a CTX-M-2 was
found in an isolate of S. sonnei resist-
ant to cefotaxime but not to cef-
tazidime (4). In South Korea, TEM-
15, TEM-17, TEM-19, TEM-20,
TEM-52, and CTX-M-14 were char-
acterized in S. sonnei (5); TEM-52
and CTX-M-14 were also widely dis-
tributed, particularly in Salmonella
spp. (6,7). In Turkey, an isolate of S.
sonnei producing CTX-M-3 was
reported (8). In Hong Kong, sequenc-
ing of 2 S. sonnei isolates showed the
presence of CTX-M-14 and CTX-M-
15 (9). Finally, in Bangladesh, 2 iso-
lates of S. sonnei with a class AESBL
were reported; they were not charac-
terized at the molecular level, but the
resistance phenotypes suggested a
CTX-M type (10).
In our case, little information on
antimicrobial drug resistance could be
obtained from Haiti because no sys-
tematic investigation on resistance in
Enterobacteriaceae is performed.
Nevertheless, the emergence of TEM-
137 (GenBank accession no.
AM286274) harbored by this import-
ed  S. sonnei isolate clearly demon-
strates that ESBL-associated shigel-
losis has emerged in Haiti and that
potentially large and severe shigel-
losis outbreaks could occur, for which
the use of azithromycin could be ben-
eficial, as illustrated in our patient.
Because treating shigellosis is becom-
ing problematic, it is essential to focus
on prevention measures such as sim-
ple rules of personal hygiene that
might drastically decrease the risk of
transmission.
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